Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Newswire

Comprehensive Real-Time News Feed for Teva Pharmaceutical Industries.

Results 1 - 20 of 686 in Teva Pharmaceutical Industries

  1. Safeguard Scientifics Announces Third Quarter 2014 Financial ResultsRead the original story

    Yesterday | GlobeNewswire

    ... Crescendo Bioscience (acquired by Myriad Genetics for $270 million); NuPathe (acquired by Teva Pharmaceutical Industries for $144 million); and ThingWorx (acquired by PTC for initial proceeds of $112 million). For more information, please visit ...

    Comment?

  2. Chicago's Media Cooperation Raises EyebrowsRead the original story

    Thursday | Courthouse News Service

    Though it vowed to protect any trade secrets it learned, Chicago plans to tell the media what its subpoena about the addictive painkiller Fentora yielded, drugmakers claim in court. Teva Pharmaceutical Industries and its subsidiary Cephalon sued the city of Chicago on Wednesday for anticipatory breach of contract.

    Comment?

  3. Organ Preservation Solutions Market to grow at a CAGR of 16.85% by 2018Read the original story

    Thursday | Emailwire.com

    ... Lifesciences CryoLife Lifeline Scientific Organ Recovery Systems Preservation Solutions Teva Pharmaceutical Industries ToleroTech Market Driver Increased Incidences of Organ Failure For a full, detailed list, view our report Market Challenge Lack of ...

    Comment?

  4. New Market Report: Myelodysplastic Syndrome - Pipeline Review, H2 2014Read the original story

    Tuesday Oct 21 | PR-inside.com

    ... harmaceuticals, Inc., Novartis AG, Eisai Co., Ltd., Pfizer Inc., Astex Pharmaceuticals, Inc., Teva Pharmaceutical Industries Limited, Cyclacel Pharmaceuticals, Inc., Celgene Corporation, Incyte Corporation, 4SC AG, Celldex Therapeutics, Inc.,

    Comment?

  5. Hypertension Therapeutic Pipeline Market Review H2 2014 in a New...Read the original story w/Photo

    Monday Oct 20 | PRWeb

    ... Corp.; Daewoong Pharmaceutical Co., Ltd.; Mitsubishi Tanabe Pharma Corporation; Teva Pharmaceutical Industries Limited; Toray Industries, Inc.; IntelGenx Corp.; Medivir AB; Compugen Ltd.; Palatin Technologies, Inc.; Cytokinetics, Inc.; Yungjin Pharm ...

    Comment?

  6. Autism and Endometriosis Therapeutic Pipeline (Company and Drugs Profiles) Review H2 2014Read the original story

    Saturday Oct 18 | Sys-Con Media

    ... Egenix, Inc., Novartis AG, Merz Pharma GmbH & Co. KgaA, Mitsubishi Tanabe Pharma Corporation, Teva Pharmaceutical Industries Limited, BrainStorm Cell Therapeutics Inc., Avanir Pharmaceuticals, Inc., Curemark, LLC, Coronado Biosciences, Inc., Omeros ...

    Comment?

  7. Chronic Pain - Pipeline Review, H2 2014 - New Market Study PublishedRead the original story

    Saturday Oct 18 | PR-inside.com

    ... Co., Ltd., Orion Corporation, Pain Therapeutics, Inc., Pfizer Inc., Purdue Pharma L.P., Teva Pharmaceutical Industries Limited, Collegium Pharmaceutical, Inc., Bionomics Limited, Acadia Pharmaceuticals Inc., Pozen, Inc., Mertiva AB, INSYS ...

    Comment?

  8. Perennial Allergic Rhinitis - Pipeline Review, H2 2014: New research...Read the original story

    Saturday Oct 18 | PR-inside.com

    ... in this Report: Shionogi & Co., Ltd., GlaxoSmithKline plc, Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Limited, FAES Farma SA, GenMont Biotech Inc., VentiRx Pharmaceuticals, Inc., Adamis Pharmaceuticals Corporation, Hanmi ...

    Comment?

  9. Osteoporosis & Osteoarthritis Therapeutic Pipeline Review (Company &...Read the original story w/Photo

    Friday Oct 17 | PRWeb

    ... Inc., TiGenix NV, Novartis AG, Astellas Pharma Inc., Chong Kun Dang Pharmaceutical Corp., Teva Pharmaceutical Industries Limited, A. Menarini Industrie Farmaceutiche Riunite Srl, Merck KGaA, Bone Medical Limited, Addex Therapeutics Ltd, Can-Fite ...

    Comment?

  10. "Constipation - Pipeline Review, H2 2014" now available at Fast Market ResearchRead the original story

    Friday Oct 17 | PR-inside.com

    ... Sumitomo Dainippon Pharma Co., Ltd., Astellas Pharma Inc., Kissei Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Limited, Shire Plc, AlbireoPharma, Sanwa Kagaku Kenkyusho Co., Ltd., Sucampo Pharmaceuticals, Inc., Ironwood Pharmaceuticals, ...

    Comment?

  11. With Strong Corporate Partnerships, Xenon Pharmaceuticals IPO Looks AppealingRead the original story w/Photo

    Thursday Oct 16 | Seeking Alpha

    XENE recently filed for an approximately $44 million NASDAQ IPO; XENE will offer 4 million shares at a target high price of $12. XENE is a clinical stage biopharmaceutical company that is focused on developing a pipeline of treatments for genetically inherited diseases.

    Comment?

  12. Canaan Partners Raises $675 Million for its Tenth FundRead the original story

    Wednesday Oct 15 | Venture Capital Access Online

    Canaan Partners, a multi-billion dollar venture capital firm, today announced that it has raised $675 million in commitments for Canaan X. Canaan Partners' tenth fund brings the total capital under management to over $4.2 billion. Fund X follows a banner year at Canaan with a dozen liquidity events in the past twelve months.

    Comment?

  13. Supreme Court seems divided in patent dispute over bestselling multiple sclerosis drugRead the original story w/Photo

    Wednesday Oct 15 | The Winnipeg Free Press

    Attorney Carter G. Phillips, representing generic drug maker Mylan Pharmaceuticals, departs the Supreme Court in Washington in Washington, Wednesday, Oct. 15, 2014, after arguments in Teva Pharmaceuticals U.S.A., Inc. v. Sandoz, Inc. Justices seem divided as it considers a high stakes patent dispute between rival pharmaceutical companies over the world's best-selling multiple sclerosis treatment, a case that threatens to cut into the $4 billion-a-year profits that Israel-based Teva Pharmaceutical Industries Ltd. earns selling the drug Copaxone.

    Comment?

  14. Canaan Partners Raises $675M for Tenth FundRead the original story w/Photo

    Thursday Oct 16 | Fox News

    Venture-capital firm Canaan Partners has raised $675 million for its tenth fund, Canaan X, bringing total assets under management to more than $4.2 billion. The announcement comes on the heels of a big year for Canaan, with 12 exits for portfolio companies in the last 12 months.

    Comment?

  15. IPO Preview: Xenon PharmaceuticalsRead the original story w/Photo

    Thursday Oct 16 | Seeking Alpha

    ... to partner with global pharmaceutical companies. XENE's pharmaceutical partners include Teva Pharmaceutical Industries, Ltd., or Teva (through its subsidiary, Ivax International GmbH), Genentech, Inc., or Genentech, and Merck & Co., Inc., or Merck ...

    Comment?

  16. Supreme Court weighs generic drug disputeRead the original story w/Photo

    Thursday Oct 16 | Bioscience Technology

    The Supreme Court seems divided as it considers a high-stakes patent dispute between rival pharmaceutical companies over the world's best-selling multiple sclerosis treatment. Justices heard arguments Wednesday in a case that threatens to cut into the profits of Israel-based Teva Pharmaceutical Industries Ltd., which sells $4 billion annually of the drug Copaxone.

    Comment?

  17. California VC Firm Raises $675M; More Than $200M Planned For HealthcareRead the original story w/Photo

    Thursday Oct 16 | Medical Device/Diagnostic Ind.

    Canaan Partners just raised $675 million. A general partner talks about how to get a shot at the roughly $200-$225 million meant for healthcare companies.

    Comment?

  18. 12 exits in 12 months helps Canaan Partners raise $675M for new fundRead the original story w/Photo

    Thursday Oct 16 | Business Journal

    Maha Ibrahim, a general partner at Canaan Partners, said that its 12 exits in 12 months made raising a new $675 million fund rather easy. Canaan Partners has closed a $675 million venture fund, bringing the total it has under management to more than $4.2 billion.

    Comment?

  19. OncoGenex Pharmaceuticals Inc. To Report Financial Results For Third...Read the original story

    Thursday Oct 16 | BioSpace

    ... of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, ...

    Comment?

  20. OncoGenex to Report Financial Results for Third Quarter 2014 on October 30, 2014Read the original story

    Thursday Oct 16 | Canada NewsWire

    ... of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, ...

    Comment?